IMVT
Immunovant, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Eric Venker
IPO Date
2019-06-21
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Immunovant, Inc.
CEO
Eric Venker
IPO Date
2019-06-21
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 106 |
| $39.99 |
| 10 Jul 2026 | Van Tuyl Christopher | Chief Legal Officer | S-Sale | Disposed | 1,143 | $39.53 |
| 10 Jul 2026 | Van Tuyl Christopher | Chief Legal Officer | S-Sale | Disposed | 63 | $39.99 |
| 10 Jul 2026 | Stout Jay S | Chief Technology Officer | S-Sale | Disposed | 1,906 | $39.53 |
| 10 Jul 2026 | Stout Jay S | Chief Technology Officer | S-Sale | Disposed | 105 | $39.99 |
| 10 Jul 2026 | Stout Jay S | Chief Technology Officer | S-Sale | Disposed | 1,399 | $39.53 |
| 10 Jul 2026 | Stout Jay S | Chief Technology Officer | S-Sale | Disposed | 77 | $39.99 |
| 6 Jul 2026 | Venker Eric | director, officer: Chief Executive Officer | M-Exempt | Acquired | 92,188 | $14.46 |
| 6 Jul 2026 | Venker Eric | director, officer: Chief Executive Officer | D-Return | Disposed | 86,629 | $38.14 |